Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

HHS aids development of next generation broad spectrum antibiotic

Date:  January 20, 2012

Company: CUBRC, Inc., of Buffalo, N.Y., and Tetraphase Pharmaceuticals of Watertown, Mass.

Contract amount: $11.4 million in the first year and can be extended an additional four years, for a total of five years and up to a total value of $67.2 million.

About the contract: This contract supports advanced development of a drug called TP-434, a novel antibiotic that potentially could treat illnesses caused by biological threats, such as anthrax and plague, as well as treat bacterial pneumonia and certain life-threatening bacterial infections associated with prolonged hospitalization. Tetraphase Pharmaceuticals currently is developing TP-434, a member of the tetracycline class of antibiotics, to treat complicated intra-abdominal infections. Early research and development indicates that TP-434 also could be effective against bacteria known to be resistant to many other antibiotics, including other tetracyclines. Today’s contract supports testing of TP-434 in clinical and animal studies as well as fine-tuning of drug manufacturing. The contract also supports development of both oral and intravenous formulations of TP-434.

Additional information: BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.

PHE Newsroom

Submit an Inquiry


Watch, Listen, Subscribe


Twitter  LinkedIn  Facebook  Instagram

Watch us on YouTube  Follow us on Flickr  Subcribe to our RSS  Subscribe to our email list

  • This page last reviewed: August 05, 2020